Tracers of radionuclide imaging
The radiopharmaceutical used is always selected in a case-specific manner. The radioisotopes most commonly used in cancer treatments are samarium, iodine, rhenium, lutetium and yttrium. The most common tracer in the imaging of cancer is fluorodeoxyglucose (FDG). The attending doctor together with the Chief Physician of Molecular Radiotherapy & Nuclear Medicine will determine the tracer that is optimal in any given situation.
Tracers available at Docrates Cancer Center
For example, FDG is a tracer which can not only be used in diagnosing of different types of cancers, but also in assessing their response to treatments. A tracer named PSMA, instead, is utilised in the overall staging of prostate cancer, and natriumfluoride (18F-NaF) is an excellent tracer for examining tumor staging to the bones.
PSMA is particularly sensitive in identifying post-operative or post-radiotherapy recurrences of prostate cancer at very low PSA-levels, as well as the dissemination of early prostate cancer to, for example, lymph nodes. PSMA imaging enables a more accurate diagnosis of prostate cancer, which means that the treatment can be better tailored using methods such as modern radiotherapy, promoting a good quality of life. Being able to accurately locate the cancer is also very important for the surgeon, among others, when planning a prostatectomy.
In addition to prostate cancer, the focus area in tracer diagnostics at Docrates is gynaecological cancers, particularly breast cancer.
MAP Medical Technologies operates in the same building as Docrates Cancer Center. It has a cyclotron for the manufacture of radionuclide tracers and a GMP-level laboratory. There are only a handful of cancer hospitals in the world that can so optimally take advantage of the location of a cyclotron and imaging equipment (PET-CT, SPECT-CT) under the same roof.
Internal radiotherapy is an effective method of treatment for metastatic prostate cancer
14.3.2023 | Docrates Cancer Center studied the effectiveness of 177Lu-PSMA treatment with a 4-week treatment interval for patients with metastatic...Read more
The number of insured patients has more than tripled in five years
9.3.2023 | In 2022, nearly 30% of revenue generated by Docrates Cancer Center’s Finnish patients came from insurance company customers,...Read more
Docrates joins EAU23 – Europe’s biggest urological event 10 – 13 March, 2023 in Milan
8.3.2023 | Docrates Cancer Center participates to EAU23 – the Europe’s biggest urological event, which will be held on 10-13...Read more
COVID-19 – Information and guidelines
14.3.2023 | In the aftermath of the COVID-19 pandemic, we have abandoned the most robust protective measures. On this page,...Read more
Why come to Docrates Cancer Center?
- Top cancer experts and effective treatments without delay.
- Individual care. You have your own care team - your doctor and your nurse.
- Front line cancer treatment. Latest medical technology combined with proven expertise in cancer care.
- Experience in treating international patients from over 60 countries. Multilingual personnel.
Mon-Thu 8 am-6 pm, Fri 8 am-4 pm (local time)